Spark Therapeutics, Inc. (ONCE) Earns “Buy” Rating from BMO Capital Markets

BMO Capital Markets restated their buy rating on shares of Spark Therapeutics, Inc. (NASDAQ:ONCE) in a report published on Wednesday. They currently have a $101.00 price objective on the biotechnology company’s stock.

A number of other research analysts have also recently issued reports on ONCE. Chardan Capital upgraded shares of Spark Therapeutics from a neutral rating to a buy rating and boosted their price objective for the company from $60.00 to $100.00 in a report on Tuesday, August 8th. SunTrust Banks, Inc. set a $101.00 price objective on shares of Spark Therapeutics and gave the company a buy rating in a report on Monday, October 16th. Zacks Investment Research cut shares of Spark Therapeutics from a hold rating to a sell rating in a report on Saturday, August 5th. Cowen and Company reiterated an outperform rating and issued a $95.00 price target (up previously from $75.00) on shares of Spark Therapeutics in a report on Thursday, August 3rd. Finally, UBS AG reiterated a buy rating and issued a $92.00 price target (up previously from $70.00) on shares of Spark Therapeutics in a report on Thursday, August 3rd. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and eighteen have given a buy rating to the company. The stock currently has a consensus rating of Buy and an average price target of $90.36.

Shares of Spark Therapeutics (NASDAQ:ONCE) traded up $0.85 during midday trading on Wednesday, reaching $73.93. 340,947 shares of the company were exchanged, compared to its average volume of 555,183. Spark Therapeutics has a 52-week low of $47.03 and a 52-week high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.79) by ($0.11). The firm had revenue of $1.90 million for the quarter, compared to analyst estimates of $1.40 million. Spark Therapeutics had a negative net margin of 1,090.11% and a negative return on equity of 60.01%. The firm’s revenue for the quarter was up 45.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.07) EPS. equities analysts forecast that Spark Therapeutics will post -7.67 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Spark Therapeutics, Inc. (ONCE) Earns “Buy” Rating from BMO Capital Markets” was posted by Week Herald and is the property of of Week Herald. If you are reading this story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this story can be viewed at https://weekherald.com/2017/11/18/spark-therapeutics-inc-once-earns-buy-rating-from-bmo-capital-markets.html.

In related news, CEO Jeffrey D. Marrazzo sold 20,000 shares of the stock in a transaction on Monday, November 13th. The shares were sold at an average price of $71.54, for a total transaction of $1,430,800.00. Following the completion of the transaction, the chief executive officer now owns 250,000 shares in the company, valued at $17,885,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Barge Joseph La sold 3,309 shares of the stock in a transaction on Thursday, November 9th. The stock was sold at an average price of $71.31, for a total transaction of $235,964.79. Following the transaction, the insider now owns 8,146 shares of the company’s stock, valued at approximately $580,891.26. The disclosure for this sale can be found here. Insiders have sold 1,099,659 shares of company stock valued at $92,457,658 in the last 90 days. 7.30% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of ONCE. Principal Financial Group Inc. raised its position in Spark Therapeutics by 0.3% during the first quarter. Principal Financial Group Inc. now owns 38,752 shares of the biotechnology company’s stock worth $2,067,000 after acquiring an additional 122 shares in the last quarter. Teachers Advisors LLC raised its position in Spark Therapeutics by 1.9% during the first quarter. Teachers Advisors LLC now owns 34,534 shares of the biotechnology company’s stock worth $1,842,000 after acquiring an additional 650 shares in the last quarter. Vanguard Group Inc. raised its position in Spark Therapeutics by 5.2% during the first quarter. Vanguard Group Inc. now owns 1,827,660 shares of the biotechnology company’s stock worth $97,487,000 after acquiring an additional 90,686 shares in the last quarter. Geode Capital Management LLC raised its position in Spark Therapeutics by 4.9% during the first quarter. Geode Capital Management LLC now owns 177,154 shares of the biotechnology company’s stock worth $9,449,000 after acquiring an additional 8,284 shares in the last quarter. Finally, BlackRock Inc. raised its position in Spark Therapeutics by 11,332.0% during the first quarter. BlackRock Inc. now owns 1,840,214 shares of the biotechnology company’s stock worth $98,158,000 after acquiring an additional 1,824,117 shares in the last quarter. 77.94% of the stock is currently owned by hedge funds and other institutional investors.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply